Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SL19+22 CAR-T for Relapsed or Refractory Non-Hodgkin Lymphoma
NCT05206071Phase 2Unknown
- Sponsor
- Senlang Bio
- Start
- May 2021
- Primary completion
- Dec 2023
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of SL19+22 CAR-T in non-Hodgkin lymphoma (NHL), sponsored by Senlang Bio. Status: unknown.
02
Drugs
SL19+22 CAR-T
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT05206071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05206071.